Link http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=4d2ca368-e7f1-4849-b6c5-5739d5c23634
Date 4/30/2016
Company Name FLX Bio
Mailing Address 561 Eccles Avenue South San Francisco, CA 94080 USA
Company Description Founded in 2015, FLX Bio Inc. is a privately-held biopharmaceutical company focused on the discovery, development and commercialization of novel immuno-oncology agents.
Proceeds Purposes The funds will be used to support further discovery and development of its pipeline of novel immuno-oncology compounds and to advance development of the company’s Phase 1 clinical compound, FLX925, a selective inhibitor of FLT3 and CDK4/6, in a proof-of-concept study in patients with acute myeloid leukemia.